Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
manganese-engineered Lactobacillus reuteri
- Development stage
- Preclinical
- Lead developer
- Huazhong University of Science and Technology
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Manganese-engineered Lactobacillus reuteri** is an experimental oral live biotherapeutic product for colorectal cancer. The product consists of *Lactobacillus reuteri* surface-engineered with manganese to enhance bacterial proliferation, glycerol metabolism, gastrointestinal survival, colorectal-tumor colonization, and production of antitumor metabolites, principally reuterin. In preclinical colorectal cancer models, MnLR was administered with glycerol as a metabolic substrate; this MnLR/Gly regimen promoted intratumoral bacterial and metabolite accumulation, selective tumor-cell killing, immunogenic cell death, dendritic-cell maturation, M1 macrophage polarization, and effector T-cell responses. The program remains preclinical; an enteric capsule formulation of MnLR plus glycerol, termed GlyMnLR, was evaluated in orthotopic rabbit colorectal cancer models. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41413024/))
- Other names
- manganese-engineered L. reuteriMnLR
02
Targets
GLUD1 (Glutamate dehydrogenase 1, mitochondrial)HIF1A (Hypoxia-inducible factor 1-alpha)MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on manganese-engineered Lactobacillus reuteri.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on manganese-engineered Lactobacillus reuteri.